Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
COMMENTARY Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
-
BUSINESS Merck Poised to Work Together with Japan towards 90% HPV Vaccine Rate: Exec
March 31, 2023
-
ACADEMIA Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL
March 30, 2023
-
REGULATORY Japan Approves Wegovy, Omvoh, FluMist, Entyvio SC and More
March 28, 2023
-
BUSINESS Novartis Japan Sees 2023 OK for 1st siRNA Drug for Hyperlipidemia, 7 Approvals to Drive Growth
March 27, 2023
-
ORGANIZATION Japan Umbrella Trade Organ to Beef Up Functions for Lobbying Activity
March 24, 2023
-
REGULATORY Generic Dispensing Tops 82%; 57% of Pharmacies Not Active on Biosimilars: Poll
March 23, 2023
-
REGULATORY MHLW Council Discusses Root Causes of Drug Supply Disruptions, Yakkasa Issues
March 22, 2023
-
REGULATORY Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
-
BUSINESS CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
March 17, 2023
-
BUSINESS Illumina Eyes Japan Launch of Comprehensive Genomic Profiling Test This Year
March 16, 2023
-
BUSINESS Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
-
BUSINESS Eisai’s Leqembi Wins Coverage from US Veteran’s Body
March 15, 2023
-
BUSINESS Bayer Setting Out to Cut Up to 480 Jobs as Xarelto Patent Cliff Looms: Employee
March 14, 2023
-
BUSINESS AstraZeneca Looks to 1st IO/ADC Launch as Leader in the Race: Oncology Head
March 13, 2023
-
ORGANIZATION PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
-
REGULATORY Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
-
REGULATORY Expert Narukawa Backs JPMA Pitch on Value-Based Pricing, but Disputes Blanket Price Maintenance for Patented Meds
March 8, 2023
-
BUSINESS Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
March 7, 2023
-
BUSINESS Drug Makers Wary of Rush Demand Tied to Unprofitability Re-Pricing, Some Curb Orders
March 7, 2023
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…